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Replication competent adenoviruses with various E1 modifications designed to restrict their replication to tumor cells are being evaluated
as oncolytic agents in clinical trials. In mouse models, we observed that such oncolytic adenoviruses showed greater hepatotoxicity than E1-
deleted adenovirus vectors following intravenous administration. Additional studies in congenic BALB/c, nude, and beige/Scid mice
demonstrated dose-dependent hepatotoxicity and indicated that beige/Scid was the most sensitive strain. Comparison of E1-containing
viruses showed that hepatotoxicity correlated with expression of wild-type E1a in the liver. Pharmacokinetic analysis showed rapid increases
in viral DNA levels in the liver with a virus containing wild-type E1a. This was correlated with rapid induction of TNF-a to high levels and
with rapid elevation of serum ALT. Hepatotoxicity was significantly reduced for an adenovirus with deletions in the region E1a (dl01/07) or a
virus lacking E1a. The results suggest a mechanism for hepatotoxicity involving virus-induced production of local TNF-a release and E1a-
mediated sensitization of hepatocyte killing.
D 2004 Elsevier Inc. All rights reserved.
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Replication competent adenoviruses with modifications
of the E1 region designed to restrict their replication to
tumor cells have shown significant antitumor efficacy in
animal models and are being evaluated as oncolytic agents
for cancer therapy in clinical trials (Biederer et al., 2002;
Kirn et al., 2001). The majority of clinical studies of
oncolytic adenoviruses has used intratumoral administra-
tion, and local tumor responses have been reported in early
phase trials in some patients treated with the E1b-deletion
mutant dl1520 (ONYX-015, Nemunaitis et al., 2001), or
an adenovirus with E1a under the control of a prostate-
specific promoter (DeWeese et al., 2001). Intravenous
administration of dl1520 up to doses of 2  1013 viral0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: heidrun.engler@canji.com (H. Engler).particles was reported to be well tolerated, although
transient dose-dependent increases of serum transaminases
were observed. Intrahepatic artery administration of dl1520
at doses up to 2  1012 viral particles, intended to increase
virus uptake in liver metastases of colorectal cancer,
resulted in a dramatic reduction in tumor size in one
patient, but drug-related elevations in serum transaminases
were observed at the highest dose level (Reid et al., 2001,
2002). Overall, these studies support the concept of using
replication competent adenoviruses for cancer therapy, but
also point out the value of developing new agents with
increased therapeutic index, particularly for hepatic artery
or intravenous administration.
Preclinical evaluation of the therapeutic index of
oncolytic adenoviruses is challenging because human
adenovirus is fastidious in its host range; antitumor efficacy
studies require the use of human tumor xenografts in
immunodeficient mice (Wang et al., 2003). Because of the
inability of the virus to replicate efficiently in mouse cells004) 52–61
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aspects of tissue or organ toxicity associated with viral
replication are very difficult to assess in preclinical models.
In this context, defining the mechanisms by which oncolytic
adenoviruses induce toxicity in mouse models would be
very useful in understanding the relationship of the animal
data to clinical data and in evaluating potential improve-
ments in therapeutic index.
In rodents and primates, hepatotoxicity is a common
dose-limiting factor for intravascular administration of
adenoviral vectors (Alemany and Curiel, 2001; Alemany
et al., 2000; Christ et al., 2000; Lieber et al., 1997; Schnell
et al., 2001). Several studies using E1-deleted replication-
defective adenoviral vectors have shown acute induction of
the proinflammatory cytokines IL-6, IL-1h, and TNF-a,
mirroring the clinical observations with similar vectors.
Data from several groups have demonstrated that these
inflammatory cytokines are elicited from macrophages by
adenovirus, inactive virions, or capsid components (Ben-
Gary et al., 2002; Christ et al., 2000; Higginbotham et al.,
2002; Lieber et al., 1997; Metcalf, 1996; Miller et al., 2002;
Morral et al., 2002; Schnell et al., 2001; Tao et al., 2001;
Wheeler et al., 2001; Worgall et al., 1997), suggesting that
viral gene expression is not required to elicit this acute
response.
In a pilot study to evaluate antitumor efficacy of a series
of oncolytic adenoviruses, we observed that these agents
showed greater hepatotoxicity than E1-deleted replication-
defective adenovirus vectors when administered intrave-
nously to immunodeficient mice bearing human tumor
xenografts (Engler et al., unpublished observations). We
also noted that toxicity occurred within 24–48 h and that the
effects at a given dose were greater when beige/Scid mice
rather than nude mice were used as the host for tumor
xenografts. Because transgene expression in livers typically
increases to maximum at 24–48 h after intravenous
administration of replication-defective adenovirus vectors
(Iqbal Ahmed et al., 2001), we hypothesized that the
increased toxicity of the oncolytic viruses compared to
E1-deleted vectors might be related to expression of viral
early genes. Because replication of human adenovirus in
mouse tissues is essentially undetectable (Paielli et al.,
2000), we further hypothesized that hepatic injury in these
animal models was associated with immune response to
adenovirus rather than due to lytic viral replication.
Several cells involved in innate immune response are
activated at early times following intravenous administration
of adenovirus, including macrophages and dendritic cells
(Korst et al., 2002; Lieber et al., 1997; Zhang et al., 2001),
NK cells (Liu et al., 2000; Ruzek et al., 2002), and neu-
trophils (Muruve et al., 1999), with concomitant induction of
inflammatory cytokines and chemokines produced by these
cells. Macrophages, in particular, are a major source of IL-
1h, IL-6, and TNF-a, which are elevated following intra-
vascular administration of adenovirus in rodents and
primates (Liu et al., 2000; Schnell et al., 2001).The well-documented ability of E1a to sensitize mouse
cells to killing by TNF-a in vitro is potentially relevant in
this context; several studies using E1a mutants have shown
that sensitization is associated with binding to Rb proteins
and with induction of cellular DNA synthesis (Chen et al.,
1987; Cook et al., 1989; Duerksen-Hughes et al., 1989;
Metcalf, 1996; Routes et al., 2000; Shisler et al., 1996).
However, the relationship of E1a expression to adenovirus
toxicity in whole animals has not been defined.
To test effects of E1a on liver toxicity, we selected a
series of viruses varying in the structure of the E1 region
and compared their effects in nontumor bearing mice. The
selected viruses carried a partial deletion of the E3 region
(Jones and Shenk, 1979), which is involved in inhibition of
host immune response (Dimitrov et al., 1997; Horton et al.,
1991). We also used three BALB/c congenic strains
differing in immune function to evaluate the relationship
of components of the immune response to development of
hepatotoxicity. Strains comprised immunodeficient nudes,
which are deficient in T-cells, and beige/Scid, which are
deficient in B-cells, T-cells, and also show defects in NK-
cells, macrophages, and neutrophile function (Appelberg et
al., 1995; Roder and Duwe, 1979).
We report here that hepatotoxicity in all three mouse
strains was associated with expression of wild-type E1a and
induction of TNF-a in the liver. Adenoviruses with wild-
type E1a genes that showed rapid increases in E1a-DNA
were correlated with rapid, high-level induction of TNF-a in
the liver and rapid elevation of transaminases (ALT) in
serum.Results and discussion
Adenovirus-mediated expression of b-gal and E1a in livers
of immunodeficient and normal mice
To compare expression levels of adenoviral vectors in the
liver, BALB/c, nude, or beige/Scid mice were treated with a
replication deficient adenovirus vector expressing E. coli h-
gal from the human cytomegalovirus major immediate early
promoter (rAd-h-gal), by intravenous injection at a dose
level of 5  109 viral particles (P) per mouse. Virus particles
were measured by ion-exchange HPLC that determines
concentrations of intact adenovirus particles relative to an
internal adenovirus standard (Shabram et al., 1997). Mice
were sacrificed 48 h post treatment, and livers from each
animal were divided into thirds for analysis. As shown in
Fig. 1A (top row), intravenous administration of 5  109 P
rAd-h-gal to beige/Scid mice resulted in extensive X-gal
staining in livers; essentially, all hepatocytes showed
evidence of h-gal expression. In contrast, only sparse X-
gal staining was observed in livers of nude and BALB/c
mice.
In parallel with the rAd-h-gal experiments, additional
groups of mice were treated with 5  109 P of the
Fig. 1. Differences in the level of gene expression depending upon the mouse strain. (A) h-gal activity (top) and IHC for E1a expression (red color; bottom) in
liver sections of beige/Scid (left), nude (middle), or BALB/c mice (right) treated intravenously with rAd-h-gal or dl309 at 5  109 P/ml. (B) Representative
liver sections of BALB/c mice treated intravenously with rAd-hgal or dl309 at 5  1011P/ml: h-gal staining (left), E1a expression (red color, right panel). (C)
Mean concentrations (FSD) of h-gal or E1a-RNA in livers as determined by QRT-PCR; n = 6/mouse strain treated with 5  109 particles; n = 3 for BALB/c
mice treated with 5  1011 particles in a separate experiment; quantification was below detection limit in livers of vehicle treated animals (n = 2). *RNA (h-gal
or E1a) levels significantly increased ( P b 0.05) compared to nudes or BALB/c.
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described by Jones and Shenk (1979) carries a partial
deletion of the E3b region responsible for blocking
cytolytic effects on adenovirus-infected cells (Gooding et
al., 1991; Horwitz, 2001; Sparer et al., 1996). Intravenous
administration of dl309 at 5  109 P to beige/Scid, nude,
and BALB/c mice resulted in extensive expression of the
adenovirus early gene E1a in livers of beige/Scid mice, as
detected by immunohistochemistry (IHC) staining for E1a
protein (Fig. 1A, lower row), but not for hexon (data notshown). Consistent with h-gal staining, only sparse E1a
staining was detected in livers of nude and BALB/c mice.
To test whether higher doses of adenovirus could over-
come the inhibition of viral gene expression in an
immunocompetent strain, we treated BALB/c mice intrave-
nously with dl309 or rAd-h-gal using a dose level of 5 
1011 P. This dose level resulted in extensive h-gal or E1a
staining in livers of BALB/c mice (Fig. 1B). Similar
results were obtained in nude mice at this dose level (data
not shown).
Fig. 2. Association of E1a expression with hepatotoxicity and increased
TNF-a expression. From same experiment as in Fig. 1, mean TNF-a
(A) and mean serum ALT (B) concentrations (FSD) observed in beige/
Scid, nudes, or BALB/c mice; data shown for BALB/c mice treated with
5  1011 particles are from a separate experiment. *Significant increase
( P b 0.05) compared to nudes or BALB/c mice in the same treatment
group.
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beige/Scid, nude, and BALB/c mice was measured at 48 h
post treatment in parallel with the histochemical staining
of proteins. RNA was extracted from portions of livers
from mice treated with rAd-h-gal or dl309 as described
above. As shown in Fig. 1C, expression levels of h-gal
and E1a RNAs in liver homogenates using quantitative
RT-PCR (QRT-PCR) correlated well with expression
levels of h-gal and E1a proteins in liver sections by
histochemical staining. QRT-PCR showed that levels of
either h-gal or E1a RNAs in livers of beige/Scid mice
were approximately 100-fold higher than those in nude or
BALB/c mice following intravenous administration of a
dose of 5  109 P of adenovirus. Treatment of BALB/c
mice with a 100-fold higher dose of dl309, 5  1011 P,
produced E1a RNA levels comparable to those observed
in beige/Scid mice treated with 5  109 P (Fig. 1C). This
data suggests that the threshold dose for adenovirus-
mediated gene expression in the liver in the highly
immunodeficient beige/Scid mice is significantly lower
than for nude or BALB/c mice.
Comparison of hepatotoxic effects of dl309 versus
rAd-b-gal in immunodeficient and normal mice
To further investigate the hepatic effects post dl309
treatment in the different mouse strains, we determined
TNF-a protein levels in the liver tissue, as well as ALT
levels in serum, as measures of hepatic inflammation and
injury. Treatment with rAd-h-gal induced a low level of
TNF-a liver tissue concentrations in all mouse strains
compared with vehicle (Fig. 2A). In contrast, treatment with
dl309 induced TNF-a in livers to levels approximately
fivefold higher in the beige/Scid mice (Fig. 2A). Together
with TNF-a elevation (beige/Scid mice), ALT increased
(Fig. 2B).
BALB/c mice treated with the higher dose of dl309 (5 
1011 P) that resulted in abundant E1a expression in
hepatocytes induced increased levels of TNF-a, as well as
increases in serum ALT comparable to those induced in
beige/Scid mice treated with dl309 at a dose of 5  109 P
(Figs. 2A, B). As expected treatment of beige/Scid mice
with rAd-h-gal at 5  109 P did not result in elevated TNF-
a or ALT, suggesting that even though transgene expression
was observed in the liver, E1a deletion of adenoviruses
reduced hepatotoxicity.
Relationship of viral genetics to hepatotoxicity.
Effects of E1a on TNF induction and sensitization have
been demonstrated in vitro using several cell types. In
studies modeling E1a effects on inflammatory cells,
upregulation of the TNF-a promoter by the 13S E1a gene
product has been shown in human monocytic and T-cell
lines (Ames et al., 1990; Metcalf, 1996; Rhoades et al.,
1996; Sanchez et al., 2002), and in lung tissue in vivo(Ginsberg et al., 1991). Correspondingly, E1a gene products
expressed in rodent fibroblast lines have been shown to
sensitize these cells to the cytotoxic effects of TNF-a (for
review see Wold, 1993). Molecular genetic studies using
E1a mutants suggested that TNF-a sensitization was
dependent on the ability of E1a to bind to either p300 or
p105-Rb (Shisler et al., 1996). The p300 and p105-Rb
binding regions of E1a are present in both the 13S and 12S
gene products.
To determine what features of dl309 were associated
with hepatotoxicity in beige/Scid mice, we compared a
series of adenoviruses derived from dl309 that differed in
genome structure in the E1 region (Table 1). This series
included the oncolytic adenoviruses dl1520 (Barker and
Berk, 1987; Heise et al., 1999), the conditionally replicating
adenovirus dl01/07(Howe et al., 1990), as well as the E1a
mutant dl312 (Jones and Shenk, 1979; Winberg and Shenk,
1984). The E1 region of the oncolytic virus dl1520 contains
intact E1a, but is defective for expression of the 55 kDa E1b
protein that binds to cellular p53 (Bischoff et al., 1996). In
contrast, the oncolytic virus dl01/07 contains intact E1b but
Table 1
Viruses with mutations in the E1 region
E1a E1b-19K E1b-55K
dl309 wild-type wild-type wild-type
dl1520 wild-type wild-type deleted
dl01/07 01/07 E1aa wild-type wild-type
dl312 deleted wild-type wild-type
a
dl01/07 has 01 and 07 deletions in the E1a region such that the E1a
protein expressed does not bind to p300 or Rb.
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to cellular p300 and Rb proteins (Howe et al., 2000), and the
E1a mutant dl312 has intact E1b but does not produce E1a
protein.
Intravenous administration of the various adenovirus
mutants resulted in delivery of comparable amounts of
virus DNA to the liver of beige/Scid mice 3 h after the
treatment as measured by QPCR using E1a region primers
and a hybridization probe that recognized wild-type E1a as
well as the dl01/07 E1a mutant (Table 2). However, 48 h
after treatment, levels of virus DNA (E1a-DNA) in the
livers of high dose dl309- or dl1520-treated animals were
approximately 10-fold higher than levels measured in
animals treated with dl01/07 (Table 2). Correlated with
the increases in E1a-DNA, dl309 at 5  109 P generated
serum ALT levels N500 U/L, more than 10-fold higher
than levels observed in vehicle or untreated animals; doses
of 5  108 P resulted in little or no ALT elevation (data
not shown). Treatment with the E1b-deleted oncolytic
adenovirus dl1520 generated dose-dependent ALT eleva-
tions similar to those of dl309 (Table 2). In contrast,
treatment with the E1a mutant oncolytic virus dl01/07 at
the 5  109 P dose resulted in ALT levels of
approximately 150 U/L, only about threefold higher than
untreated, or vehicle control levels. Treatment with dl312,
a mutant that does not express E1a protein, did not result
in elevated ALT levels, indicating that expression of E1A
protein may be correlated to the observed hepatotoxicity
(Table 2).Table 2
Increases in ALT and TNF a in beige/Scid mice following treatment with differe
Treatment E1a-DNA
copies/mg 
105 at 3 h
E1a-DNA
copies/mg 
107 at 48 h
dl309 20.2 F 11.0 55.8 F 9.0a
dl1520 19.4 F 12.0 49.3 F 8.6a
dl01/07 24.3 F 13.2 3.7 F 1.1a,b
dl312 20.4 F 14.3 BQL
vPBSc BQL BQL
untreated BQL BQL
BQL: below quantification limit ( N10 copies/mg).
a Significantly increased compared to copies detected 3 h after treatment.
b Significantly reduced compared to dl309 or dl1520 treatment.
c Vehicle control.Relationship of mutation in E1a and viral DNA synthesis to
hepatic inflammation and injury
Because comparable amounts of virus were delivered to
the liver, as measured by virus DNA concentrations at 3 h
after administration (Table 2), the differences of hepatotox-
icity among the E1a-expressing mutants, for example,
higher toxicity after dl309 or dl1520 treatment, but lower
toxicity in the dl01/07 group, may have been the result of
differences in onset of E1a-DNA synthesis in the liver
before undergoing an abortive but lytic infection as
described by Duncan et al. (1978). To further address these
questions, we designed a time course study to investigate
the relationship between maximal viral DNA concentra-
tions, induction of TNF-a, and hepatotoxicity. The oncolytic
adenoviruses dl1520 or dl01/07 were administered intra-
venously to beige/Scid mice; livers were harvested over a
14-day time course. Blood samples were taken for
determination of serum ALT levels. Liver pathology (two
sections of every major liver lobe) was evaluated by an
independent pathologist.
Semiquantitative evaluation of E1a by IHC indicated
comparable expression in livers of mice treated intra-
venously with either dl1520 or dl01/07 (data not shown).
However, although identical levels of dl1520 or dl01/07
E1a-DNAwere delivered to the liver 3 h after administration
(Fig. 3A), increases in viral DNA concentrations in the
dl1520 treatment group on day 2 indicated a possible onset
of E1a-DNA synthesis. At the same time virus DNA
increased, ALT levels in dl1520-treated mice increased to
high levels (Fig. 3B), paralleled the increases in TNF-a
(Fig. 3C), and resulted in hepatotoxicity in this treatment
group (Fig. 4). In contrast, levels of dl01/07 DNA were
lower at 48 h due to either delayed onset, or reduced
synthesis of new dl01/07 E1a-DNA. E1a-DNA persisted or
increased only slightly from days 2 through 7 (Fig. 3A).
Although there was an increase in E1a-DNA (Fig. 3A) and
TNF-a levels in dl01/07-treated mice at day 7, serum ALT
increased only slightly (Figs. 3B, C). Taken together, thent adenovirus mutants
ALT (U/L)
at 48 h
TNF-a-RNA
(fold increase
compared to
control) at 48 h
Liver necrosis
at 48 h
539 F 88 12.9 F 4.6 ++++
387 F 43 11.2 F 3.8 ++++
136 F 26b 8.4 F 3.9 no pathology
23 F 3 1 no pathology
43 F 26 1 no pathology
36 F 17 1
Fig. 3. Time-course of viral copies (E1a-DNA) and TNF-a in livers and
changes in serum ALT after treatment with dl1520 or dl01/07. DNA
concentrations of E1a in liver homogenates were determined by Q-PCR.
Data from 3 h samples are shown as 0 day samples. (A) Viral DNA (E1a
region) concentrations (copies/mg tissue) of the individual animals treated
with dl1520 (open circle, mean = broken line) and dl01/07 (filled diamond,
mean = solid line) over time. (B) Mean (FSD) serum ALT concentrations
(filled circle) following treatment with dl1520 (broken line), dl01/07 (solid
line); (C) mean (FSD) of TNF-a RNA upregulation in liver tissue (fold
increase compared to TNF-a in vehicle-treated animals); n = 6 animals
(days 2 and 7); 3 animals (days 4, 10, and 14) *significant increase ( P b
0.05), dl1520 group compared to dl01/07 group (day 2); **significant
increase ( P b 0.05), dl01/07 group compared to dl1520 group (day 7).
Fig. 4. Hepatotoxicity caused by dl1520. H&E staining of a representative
liver section of an animal sacrificed 14 days after dl1520 treatment (left:
100  magnification; right: same section, 200  magnification) showing
severe hepatocellular disorganization, and multifocal necrosis.
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group), which resulted in a host immune response to rapidly
destroy dl1520-infected liver cells as indicated by elevationby serum ALT. This fulminant process by hepatocyte death
may have been reason for the observed liver necrosis (Fig.
4). The delayed onset in virus DNA and TNF-a RNA
accumulation as well as reduced susceptibility to TNF-a cell
killing on the other hand may have lowered the toxicity in
the dl01/07 group.
Previous studies (Heise et al., 1999; Johnson et al., 2002)
indicate that hepatic necrosis is the major dose limiting
toxicity in mice following intravenous administration of
replication competent adenoviruses. Expression of E1a
triggers proapoptotic host cell responses during adenovirus
infection because of its cell cycle deregulation functions in
quiescent cells, which are required for replication of viral
DNA (reviewed by Ben-Israel and Kleinberger, 2002). In
addition to the activation of an intrinsic pathway, host
immune responses trigger the release of TNF-a (Wold et al.,
1999). TNF-a binds to its cognate receptors TNF receptor 1
(TNF-R1), which is responsible for induction of apoptosis
through recruitment of TRADD, FADD, and procaspase-8
(Wallach et al., 1999). This TNF-R1 signaling pathway has
been identified as one of the mechanisms responsible for
immunomediated killing of adenovirus-infected hepatocytes
(Liu et al., 2000).
The data presented here suggest an in vivo model to
demonstrate E1a-mediated hepatotoxicity. The data show
that hepatotoxicity in mouse models is dependent both on
the immune competence of the host and the expression of
virus early proteins. The reason that beige/Scid mice were
more sensitive to adenovirus-mediated hepatic injury may
be impairment of the innate immune response resulting in
insufficient clearance. In immune competent animals, most
of the systemic administered adenovirus is sequestered and
cleared from Kupffer cells, and gene expression in
hepatocytes can be achieved with high doses (Alemany et
al., 2000; Tao et al., 2001) leading to a nonlinear dose
response of transduction of hepatocytes (Tao et al., 2001).
High gene expression after treatment with lower viral doses
(5  109 P) in beige/Scid mice compared to BALB/c or
nude mice (5  1011 P) may have been due to a reduced
sequestration of adenovirus by Kupffer cells. Similar
observations were reported in Rag-1 mice, which compara-
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not produce any significant level of immunoglobulins
needed for opsonization of adenovirus for efficient uptake
by Kupffer cells (Tao et al., 2001). Therefore, increased
infection of hepatocytes could trigger an elevation of TNF-a
tissue concentrations released from activated tissue macro-
phages in beige/Scid mice.
Fulminant hepatotoxicities caused by adenovirus are
known in severe immune suppressed patients after bone
marrow transplantation (Wang and Wang, 2003). Even
though beige/Scid mice are only a model system, reduced
liver toxicity in beige/Scid mice may predict an increased
therapeutic index for oncolytic viruses such as dl01/07 that
has demonstrated tumor inhibition in a variety of preclinical
tumor models (Howe et al., 2000). Correlation of preclinical
data from these mouse models with data from human
clinical trials will provide a means of assessing the relative
importance of the various immune effector functions to
toxicity and efficacy of oncolytic adenoviruses.Material and methods
Adenoviruses
Attenuated replicating viruses dl01/07 and dl1520 were
kind gifts of S. Bayley (McMaster University, Hamilton) and
A. Berk (UCLA), respectively. All these viruses contained
deletions in E3 region as in dl309 (Fig. 3), a phenotypically
wild-type adenovirus (Jones and Shenk, 1979). dl01/07
contained the deletion in E1a between amino acids 4 and 25
and a deletion between amino acids 111 and 123, which
abolishes binding of E1a to p300 and p105-Rb, respectively
(Egan et al., 1988; Howe et al., 1990, 2000). dl1520, with
the full E1a region conserved, contained a deletion between
nucleotides 2496 and 3233 in the E1b region and a
termination codon at the third position of E1b55K protein
(Barker and Berk, 1987). The mutant dl312 contained a
deletion between nucleotide 448 and 1349 in the E1a region
(Jones and Shenk, 1979; Winberg and Shenk, 1984). rAd-h-
gal was a complete E1-deleted virus with an insertion of the
lacZ reporter (Wills et al., 1994).
Except dl1520, all viruses were grown on A549 cells
(dl1520 was grown on 293 cells), purified by HPLC
(Huyghe et al., 1995), and concentrations determined in
particles/ml (P) upon elution from a Resource Q anion-
exchange HPLC (Shabram et al., 1997). The purified viruses
were formulated in Dulbecco’s PBS buffer containing 3%
sucrose and 2 mM MgCl2. Viruses were stored at 70 8C
until use and thawed in cold water shortly before use.
Animal studies
For the studies, female mice with 20–25 g body weight
(Taconic) were used all in the BALB/c genetic background:
(1) Fox Chase Scid-Beige mice (beige/Scid) that are lackingT and B lymphocyte function and have impaired macro-
phage and NK cell functions; (2) BALB/c nudes (nu/nu), a
mouse strain with T-cell deficiency; and (3) BALB/c, a fully
immune competent mouse strain. The mice were kept in a
barrier animal facility in groups of 10 animals/cage, a 12-h
light cycle, and sterile food and water. All experimental
protocols were approved by IACUC.
Mice were administered with different adenoviruses,
intravenous route, at a volume of 0.2 ml/dose. The animals
were euthanized at different times after treatment. Parts of
the livers were either OTC embedded for X-gal staining
(frozen sections) or formalin fixed, and paraffin embedded
(H&E staining and Immunohistochemistry). The other part
of the liver was snap frozen and homogenized for
quantitative analysis of tissue TNF-a, rAd-h-gal, or viral
E1a. Blood was collected by heart puncture to determine
transaminases, or serum TNF-a.
ALT assay
Whole blood was centrifuged and ALTconcentrations (U/
L) determined using the Cobas Mira autoanalyzer (Roche).
TNF-a bioassay
TNF-a was measured in liver homogenates using the
bioassay described by Gershenwald et al. (1990) with the
TNF-a-sensitive WEHI 164 clone 13 murine fibrosarcoma
cell line, which is a highly sensitive and specific cell line used
for TNF-a activity determination (Eskandari et al., 1990).
Briefly,WEHI-164 cells were seeded in 96-well tissue culture
plates at a density of 50,000 cells per well and incubated
overnight at 37 8C in a 5%CO2 incubator. Twenty microliters
from the supernatants of the liver homogenates were added to
the cells in the presence of 1 Ag/ml actinomycin D (Sigma).
Cell viability was assessed using the MTT-Kit (Promega)
according to the manufacturer’s instructions. A neutralizing
antibody to muTNF-a (R&D systems), added to the liver
homogenates at a concentration of 100 Ag/ml for 30 min
before the test, neutralized the cytotoxic effects on WEHI
cells by 100%. The sensitivity of the assay was 30–1860 pg of
TNF-a per gram of liver homogenate.
Serum TNF-a was evaluated using a commercially
available ELISA-Kit (Pierce).
Real-time PCR/RT-PCR (Taqman) analysis
Real-time quantitative PCR and RT-PCR (QPCR and
QRT-PCR) were as used to quantify virus DNA from the
E1a region (QPCR), E1a RNA, and TNF-a RNA (QRT-
PCR) using Sequence Detector 7700 (Taqman, Applied
Biosystems) as reported previously (Wen et al., 2000).
Briefly, livers were homogenized and total RNA and DNA
were simultaneously extracted from approximately 100 mg
of liver tissue using Tri-Reagent (Molecular Research
Center). Extracted RNA was further treated with DNAse I
(Ambion) to remove residual DNA. The complete removal
of DNAwas confirmed by PCR. Serially diluted virus DNA
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quantify viral DNA levels, and the results were expressed
as copies/milligram tissue. For RNA quantification, serially
diluted total RNA from adenovirus-infected A549 cells was
used to quantify E1a RNA and the results expressed as
MEQ (molecular equivalents). The primers used to analyze
E1a were amplifying a region residing in E1a of dl309,
dl1520, and dl01/07; E1a primers
Forward: 5V-CTCTTGAGTGCCAGCGAGTAGA-3V.
Reverse: 5V-TGTCTCATTTTCAGTCCCGGT-3V.
Probe: FAM-TTTCTCCTCCGAGCCGCTCCGA-
TAMRA.
The primers and probes to detect rAd-h-gal were
described previously (Rahman et al., 2001).
The TaqMan cytokine detection Kit (Applied Biosys-
tems) was used for analysis of TNF-a-RNA.
E1a/hexon-immunohistochemistry
Slides were prepared from paraffin-embedded liver
tissues (5-Am sections). Sections were deparaffinized and
microwave antigen retrieval was used before application of
the primary antibody (2 h incubation time). After three
successive washes with PBS, a secondary antibody and AEC
Chromogen staining was applied (AEC Kit, DACO).
Samples were counterstained with hematoxylin. Photographs
were obtained using a Nikon Optiphot microscope (100)
and a Hamamatsu CCD video system (C5810); E1a-anti-
body: (13 S-5, Santa Cruz); Hexon-antibody (Chemicon).
X-gal staining
Slides from frozen sections (5 Am) were fixed (2%
neutral buffered formalin, 2% glutaraldehyde, 2 mM
MgCl2, 10 mM PBS) for 20 min. Slides were washed
for 24 h at 4 8C (2 mM MgCl2, 0.1% sodium deoxycholate,
0.2% IGEPAL-20, 10 mM PBS, pH 7.4) followed by
immersion for 24 h at room temperature into X-gal substrate
(Invitrogen). Slides were H&E counterstained.
Pathologic evaluation
Two pieces from all major liver lobes were paraffin
embedded and two sections about 1 cm apart per block
H&E stained for pathologic evaluation. Pathology was
assessed by an independent pathologist and liver pathology
staged as follows: ++++ (severe); +++ (moderate); ++
(minor); + (minimal).
Statistics
Unpaired t test (Statview, Abacus) was used for
comparison of treatment groups. A P value b0.05 was
considered statistically significant.Acknowledgments
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